The largest database of trusted experimental protocols

Sustiva

Manufactured by Bristol-Myers Squibb
Sourced in United States

Sustiva is an antiretroviral medication used in the treatment of HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by inhibiting the activity of the HIV reverse transcriptase enzyme, which is essential for the virus to replicate.

Automatically generated - may contain errors

3 protocols using sustiva

1

Delamanid and Efavirenz Combination Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
Delamanid tablets were manufactured by Otsuka Pharmaceutical Co., Ltd. (Japan). Efavirenz was supplied as commercially available Sustiva manufactured by Bristol-Myers Squibb (USA). Subjects were randomly assigned to receive one of the following two treatments: group 1 received 600 mg of efavirenz (one 600-mg Sustiva tablet) once daily for 10 days and group 2 received 100 mg of delamanid (two 50-mg tablets) twice daily for 7 days, followed by 100 mg of delamanid twice daily plus 600 mg of efavirenz once daily for 10 days, for a total of 18 days of dosing. Consistent with labeling, the once-daily dose of efavirenz in both groups was administered in the evening at about 8 p.m. on an empty stomach (2 h after a standard meal and 2 h prior to a snack) (20 ). The first dose of delamanid was the evening dose administered on day 1, and the last delamanid dose was the evening dose administered on day 18. Each evening dose of delamanid was administered at about 6 p.m., and each morning dose of delamanid was administered at about 8 a.m.; all delamanid doses were given within 30 min of the start of a standard meal.
+ Open protocol
+ Expand
2

Dissolution and Characterization of Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lansoprazole was purchased by Sigma-Aldrich (Milan, Italy) and was dissolved at 20 mM in DMSO in absence of direct light and reconstituted immediately prior its use. Efavirenz was purified from commercially available Sustiva (Bristol-Myers Squibb) as described [3 (link)], dissolved in DMSO and added to the culture medium in the indicated concentrations and times. RPMI-1640 cell culture medium (BE12-702F), antibiotics (DE17-603E), phosphate buffer saline (PBS) (BE17-512F), trypsin/EDTA (BE17-171E) and fetal bovine serum (DE14-701F) were obtained from Lonza (Milan, Italy). Trypan blue was bought from Alexis Biochemicals (Florence, Italy) and Annexin V-FITC Apoptosis detection kit from Enzo Life Sciences (Lausen, Switzerland). 4-Nitrophenyl phosphate disodium salt hexahydrate tablets for proliferation assay was from Sigma-Aldrich.
The pH of all cell culture supernatants were estimated by the use of a pH 123 Microprocessor pH Meter (Hanna Instruments, Italy).
+ Open protocol
+ Expand
3

Bioequivalence Criteria for ARV Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
The acceptable reference products for emtricitabine, tenofovir, lamivudine and efavirenz in single formulation or FDCs for demonstrating bioequivalence are as follows: Emtriva ® (emtricitabine) 200 mg capsule, Gilead Sciences; Viread ® (tenofovir disoproxil fumarate) 300 mg tablet, Gilead Sciences; Epivir ® (lamivudine) 150 mg and 300 mg tablet, GlaxoSmithKline; Sustiva ® (efavirenz) 100 mg and 200 mg capsule, 600 mg tablet Bristol-Myers Squibb; Truvada ® (tenofovir disoproxil fumarate/emtricitabine) 300/200 mg tablet, Gilead Sciences; and Atripla ® (tenofovir disoproxil fumarate/efavirenz/emtricitabine) 300/600/200 mg tablet, Bristol-Myers Squibb and Gilead Sciences.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!